Pulmonary function, computerized tomography features and six-minute walk test at three months in severe COVID-19 patients treated with intravenous pulsed methylprednisolone: a preliminary report



  • Cristiano van Zeller Department of Cardiothoracic Medicine and Department of Respiratory Medicine, St George’s University Hospital, London, United Kingdom. https://orcid.org/0000-0001-8289-0550
  • Asad Anwar Department of Cardiothoracic Medicine and Department of Intensive Care, St George’s University Hospital, United Kingdom. https://orcid.org/0000-0002-8493-6142
  • Nordita Ramos-Bascon Department of Cardiothoracic Medicine, St George’s University Hospital, United Kingdom.
  • Natalie Barnes Department of Cardiothoracic Medicine, St George’s University Hospital, United Kingdom.
  • Brendan Madden | Brendan.madden@stgeorges.nhs.uk Department of Cardiothoracic Medicine and Department of Intensive Care, St George’s University Hospital, United Kingdom. https://orcid.org/0000-0001-7768-9182


COVID-19 ARDS has a high mortality and few therapeutic options. We present a preliminary report on our experience using high-dose pulsed methylprednisolone in COVID-19 ARDS and three-month outcomes. We performed a retrospective analysis of all patients treated with high-dose methylprednisolone for COVID-19 ARDS and three-month lung function, 6MWT, and CT findings. 15 patients were treated of which 10 survived to discharge. Reduced DLCO was the commonest abnormality in lung function tests and had the lowest mean value. Parenchymal bands were the commonest CT finding and 50% of patients had fibrosis at three-months. Mean 6MWD was 65.4% predicted and was abnormal in 62.5% of patients. In this cohort of patients with COVID-19 ARDS treated with high-dose methylprednisolone pulses, CT, lung function, and 6MWT abnormalities were unsurprisingly common at three months, although all 10 patients treated early in their disease course survived, a possible therapeutic effect. Further randomised controlled trials are needed to assess the benefits of this treatment.



PlumX Metrics


Download data is not yet available.


Vetter P, Lan Vu D, L’Hullier AG, et al. Clinical features of COVID-19. BMJ 2020;369:m1470. DOI: https://doi.org/10.1136/bmj.m1470

Grasselli G, Tonetti T, Protti A, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. Lancet Respir Med 2020 8:1201-08. DOI: https://doi.org/10.1016/S2213-2600(20)30370-2

Jordan RE, Adab P, Cheng KK. COVID-19: risk factors for severe disease and death. BMJ 2020;368:m1198. DOI: https://doi.org/10.1136/bmj.m1198

Bompard F, Monnier H, Saab I, et al. Pulmonary embolism in patients with COVID-19 pneumonia. Eur Respir J 2020;56:2001365. DOI: https://doi.org/10.1183/13993003.01365-2020

Wang L, Chen F, Bai L, Yi Q, Peng Y. In situ pulmonary thrombosis in patients with COVID-19 pneumonia: different phenotypes may exist. Thromb Res 2020;196:S41-2. DOI: https://doi.org/10.1016/j.thromres.2020.10.022

McGonagle D, O’Donnel JS, Sharif K, et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2020;2:e437-45. DOI: https://doi.org/10.1016/S2665-9913(20)30121-1

Tay MZ, Poh CM, Renia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020;20:363-74. DOI: https://doi.org/10.1038/s41577-020-0311-8

UK Government. Selected NHS patients to access coronavirus treatment Remdesivir. Accessed: 11/10/2020. Available from: https://www.gov.uk/government/news/selected-nhs-patients-to-access-coronavirus-treatment-remdesivir

UK Government. World first coronavirus treatment approved for NHS use by Government. Accessed: 11/10/2020. Available from: https://www.gov.uk/government/news/world-first-coronavirus-treatment-approved-for-nhs-use-by-government

Ngai JC, Ko FW, Ng SS, et al. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology 2010;15:543-50. DOI: https://doi.org/10.1111/j.1440-1843.2010.01720.x

Ahmed H, Patel K, Greenwood DC, et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalization and ICU admission: a systematic review and meta-analysis. J Rehab Med 2020;52:jrm00063. DOI: https://doi.org/10.2340/16501977-2694

Mo X, Jian W, Su Z, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J 2020;55:20011217. DOI: https://doi.org/10.1183/13993003.01217-2020

Frija-Masson J, Debray M-P, Gilbert M, et al. Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection. Eur Respir J 2020;56:2001754. DOI: https://doi.org/10.1183/13993003.01754-2020

Huang Y, Tan G, Wu J, et al. Impact of Coronavirus 2019 disease on pulmonary function in early convalescence phase. Respir Res 2020;21:163. DOI: https://doi.org/10.1186/s12931-020-01429-6

Zhao Y-M, Shang Y-M, Song W-B, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine 2020;25:100463. DOI: https://doi.org/10.1016/j.eclinm.2020.100463

Yam L Y-C, Lau A C-W, Lai F Y-L et al. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infecti 2007;57:28-39. DOI: https://doi.org/10.1016/j.jinf.2006.01.005

Edalatifard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomized control trial. Eur Respir J 2020;56:2002808. DOI: https://doi.org/10.1183/13993003.02808-2020

The Pharmaceutical Journal. Everything you need to know about the COVID-19 therapy trials. Royal Pharmaceutical Society. Accessed: 2/12/2020. Available from: https://www.pharmaceutical-journal.com/news-and-analysis/features/everything-you-need-to-know-about-the-covid-19-therapy-trials/20208126.article?firstPass=false

Asad A, Ramos-Bascon N, Barnes N, Madden B. A specialised cardiorespiratory team approach in the intensive care management of COVID-19 patients: benefit on mortality, diagnosis and management. Clin Med (Lond) 2021;12:101-6. DOI: https://doi.org/10.7861/clinmed.2020-0788

Madden BM, Hodson ME, Tsang V, et al. Intermediate-term results of heart-lung transplantation for cystic fibrosis. Lancet 1992;339:1583-7. DOI: https://doi.org/10.1016/0140-6736(92)91842-V

Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 2013;143:814-24. DOI: https://doi.org/10.1378/chest.12-0741

National Institutes of Health. Clinical Presentation of People with SARS-CoV-2 Infection. Accessed: 2/12/2020. Available from: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-presentation

World Health Organisation, Clinical Management of severe respiratory infection (SRI) when COVID-19 disease is suspected. Accessed: 2/12/2020. Available from: https://apps.who.int/iris/bitstream/handle/10665/331446/WHO-2019-nCoV-clinical-2020.4-eng.pdf?sequence=1&isAllowed=y

Liu D, Zhang W, Pan F, et al. The pulmonary sequelae in discharged patients with COVID-19: a short-term observational study. Respir Res 2020;21:125. DOI: https://doi.org/10.1186/s12931-020-01385-1

Wang Q, Jiang H, Xie Y, et al. Long-term clinical prognosis of human infections with avian influenza A (H7N9) viruses in China after hospitalization. EClinicalMedicine 2020;20:100282. DOI: https://doi.org/10.1016/j.eclinm.2020.100282

Hanley B, Naresh KN, Roufosse C, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe 2020;1:e245-53. DOI: https://doi.org/10.1016/S2666-5247(20)30115-4

RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report. N Engl J Med 2021;384:693-704. DOI: https://doi.org/10.1056/NEJMoa2021436

Fernandez-Cruz A, Ruiz-Antorán B, Muñoz-Gómez A, et al. A Retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality. Antimicrob Agents Chemother 64:e01168-20. DOI: https://doi.org/10.1128/AAC.01168-20

Cellajs Rubio JL, Luna del Castillo JD, de la Hera Fernandéz J, et al. Effectiveness of corticoid pulses in patient with cytokine storm syndrome induced by SARS-CoV-2 infection. Med Clin (Barc) 2020;155:159-61. DOI: https://doi.org/10.1016/j.medcle.2020.07.002

So C, Ro S, Murakami M, et al. High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series. Respirol Case Rep 2020;8:e00596. DOI: https://doi.org/10.1002/rcr2.596


COVID-19 - Collection of articles on the Coronavirus outbreak
COVID-19, acute respiratory distress syndrome, pulmonary fibrosis, corticosteroids, lung function
  • Abstract views: 783

  • PDF: 153
How to Cite
van Zeller, Cristiano, Asad Anwar, Nordita Ramos-Bascon, Natalie Barnes, and Brendan Madden. 2021. “Pulmonary Function, Computerized Tomography Features and Six-Minute Walk Test at Three Months in Severe COVID-19 Patients Treated With Intravenous Pulsed Methylprednisolone: A Preliminary Report”. Monaldi Archives for Chest Disease, July. https://doi.org/10.4081/monaldi.2021.1811.

Most read articles by the same author(s)